A quick update to our exclusive Vitiligo Drug Pipeline Analysis and Market Insights, which helps you understand competitive environment for vitiligo therapies and the key biotech companies involved in vitiligo drug development.
- Avita Medical recently announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption application to evaluate the safety and effectiveness of the RECELL® System for repigmentation of stable vitiligo lesions. Avita’s technology creates a suspension of pigment-producing cells from a small piece of the patient's own normal skin, necessary to regenerate natural healthy epidermis, in under 30 minutes. This suspension is then sprayed onto the patient's white lesions. The healing process takes from several weeks to several months, depending on the lesion size and location. The company will begin a 24-week pilot study with 10 patients in the first half of 2020.
- Arcutis Biotherapeutics in-licensed from Chinese company Jiangsu Hengrui Medicine Co an active pharmaceutical ingredient in ARQ-252, a potent and highly selective inhibitor of janus kinase type 1 (JAK1). Many signaling molecules rely on the JAK pathway — especially JAK1 — which plays a central role in immune system function. Arcutis believes this compound has a promising treatment potential without hematopoietic adverse effects typically associated with JAK2 inhibition. Arcutis anticipates initiating a Phase 2a study in the second half of 2020 to evaluate ARQ-252 as a potential treatment for vitiligo. The privately held company raised $166M to develop three dermatological drug candidates.
- Bioniz Therapeutics / Almirall has leveraged its proprietary multi-cytokine inhibitor platform technology to develop BNZ-1 for an immuno-dermatology franchise in vitiligo, cutaneous T-cell lymphoma and alopecia areata. The lead product candidate has completed Phase 1 SAD and MAD clinical trials in healthy volunteers and is currently in Phase1/2a clinical development in CTCL. The closing of the option agreement by Almirall to buy Bioniz for $62M, plus additional milestone payments and royalties, will result in the generation of a Bioniz NewCo sometime in 2020.
The full report - including analysis of 20+ biotech startups with vitiligo therapeutics in the pipeline - is posted here, exclusively for VR Foundation readers.
- Does halo nevi affect vitiligo development?
Halo nevi — nevi with an depigmented circle around it, usually on the trunk — are about 10x more common in vitiligo patients than in the general population, especially in childr...
- What are risks of oral and topical corticosteroids?
Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...
- Will it spread?
Vitiligo activity may vary considerably from person to person. In a good number of patients the disease goes on for 3-4 years and then it settles down, with one or two stubborn...
Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.